Lyell Immunopharma, Inc. (LYEL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 12.74 |
| Open | 13.06 |
| Day High | 13.06 |
| Day Low | 11.67 |
| 52-Week High | 45 |
| 52-Week Low | 8.46 |
| Volume | 175,056 |
| Average Volume | 96,906 |
| Market Cap | 279.31M |
| PE | -0.88 |
| EPS | -13.64 |
| Moving Average 50 Days | 18.5 |
| Moving Average 200 Days | 20.77 |
| Change | -0.77 |
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09,
Lyell Immunopharma Announces Participation in March Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, toda
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
GlobeNewswire Inc.
Feb 12, 2026 12:30 PM GMT
PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line s